Changchun High And New Technology Industries (Group) Inc(000661) ( Changchun High And New Technology Industries (Group) Inc(000661) ) on the evening of March 14, it was announced that the State Food and Drug Administration agreed to conduct a clinical trial of leuprorelin injection emulsion, a clinical study to evaluate the safety and effectiveness of leuprorelin injection emulsion in the treatment of advanced prostate cancer Changchun High And New Technology Industries (Group) Inc(000661) said that in view of the need to carry out relevant clinical research on leuprorelin injection emulsion and the uncertainty of listing approval after the study, it is impossible to predict its impact on the company’s future performance.
© China Stock Market News